gel column and eluted with a benzene-hexane mixture. The yields of the alkoxycoumarins were **4040%.** The physical and spectral characteristics of a few coumarins as representatives are given in Table 111.

Solubilization of Reactants in Micellar Solutions. Weighed **amounts** of powdered alkoxycoumarins were stirred for **12-24** h with **60-80** mL of the surfactant solutions (SDS, CTAB) of concentrations well above critical micelle concentrations (cmc's of SDS and CTAB are 8×10^{-3} and 9.5×10^{-4} M, respectively). The micellar solutions were filtered through Whatman No. **1** fiiter paper to remove suspended particles, if any. By a similar procedure micellar solutions containing both coumarin and benzophenone were **also** prepared.

Irradiation and Workup Procedure. The clear transparent micellar solutions were irradiated in Pyrex tubes with a **450-W** medium-pressure mercury arc lamp (Applied Photophysics Ltd.) for **5-72** h. Bulk irradiations in organic solvents and in aqueous media were also carried out in Pyrex vessels under similar conditions. Irradiations in deuterated organic solvents were carried out in Pyrex NMR tubes. During the course of irradiation the dimer formed in the micellar and aqueous phases precipitate out, on account of its lower solubility in the medium. Due to this, some of the irradiation mixtures become turbid after few hours of exposure. However, prolonged irradiation resulted in neat separation of crystalline products.

These precipitated products from the micellar solutions were collected by filtering the solutions through either a **G-4** sintered crucible or Whatman No. **1** filter paper, washed thoroughly with water, and dried slowly in air/air oven. The filtrates were diluted
to a concentration that was approximately one-third of the respective cmc's and extracted with ether or chloroform. The contents of the aqueous irradiation mixture were collected by extracting with chloroform. The products in the organic residue were separated from the reactants by preparative TLC (silica gel/benzene-chloroform mixture), purified by recrystallization (chloroform-carbon tetrachloride mixture), and analyzed spectroscopically.

Structure of the Dimers. All dimers had elemental analyses (C, H) within calculated values (0.35%). Spectral properties of a few selected dimers are presented in Table IV. The dimers formed upon direct irradiation of **1-12** in organic, aqueous, and

micellar media show a closely similar pattern for the aromatic protons $(H_5, H_6, and H_8)$ in the NMR spectrum. All these dimers have been assigned the syn head-tail configuration on the basis of the structure of 7-methoxycoumarin **(1)** dimer which has been unequivocally solved by X-ray analysis.¹⁰ The protons H_5 , H_6 , and H₈ of the dimers of 1-12 can be described as part of an AMX system. In comparison with the same protons of the monomer, $H₅$ and $H₆$ are slightly shifted upfield while $H₈$ is shifted to a higher field by over 0.6 ppm. This strong shielding effect on H_8 caused by the diamagnetic anisotropy of a phenyl nucleus situated in front of this proton is possible only in the syn head-tail configuration⁸ shown below.

The benzophenone-sensitized irradiation products of **4 methyl-7-alkoxycoumarins 7-12** were assigned the anti head-tail configuration by the 'H NMR spectrum of the dimer obtained from **7.** At 6 **3.39** and **1.25** two peaks were observed due to cyclobutane protons and cyclobutane methyl protons, respectively. These protons absorb considerably higher than the corresponding protons in the syn configuration. This shielding effect due to diamagnetic anisotropy effect of both the carbonyl group and the phenyl nucleus is possible in the anti head-tail configuration.

Registry No. 1, 531-59-9; 2, 71783-00-1; 3, 71783-02-3; 3 (syn-HT dimer), **85389-91-9; 4, 85389-84-0; 5, 85405-69-2; 6, 85389-85-1; 6** (syn-HT dimer), **85389-92-0; 7,2555-28-4; 7** (anti-HT dimer), **85389-95-3; 8,85389-86-2;** 8 (syn-HT dimer), **85389-93-1; 9,85389-87-3; 10,85389-88-4; 11,85389-89-5; 11** (syn-HT dimer), **85389-94-2; 12, 85389-90-8.**

Synthesis of Novel 3-Methylstatine Analogues. Assignment of Absolute Configuration'*

Megumi Kawai, Amrit S. Boparai, Michael S. Bernatowicz, and Daniel H. Rich*

School *of* **Pharmacy, University** *of* **Wisconsin-Madison, Madison, Wisconsin 53706**

Received September 20, 1982

The synthesis and stereochemical assignments of two new analogues of statine are reported. Boc-L-leucine was reacted with methyllithium in dimethoxyethane to produce the corresponding methyl ketone in **45-75%** yield. Addition **of** ethyl lithioacetate at **-78** "C to the methyl ketones gave **Boc-(S)-4-amino-3-hydroxy-3,6** dimethylheptanoic acid ethyl ester [Boc-Me3&-OEt] in **75-78%** yield **as** a mixture of 3-position diastereomers. The corresponding Me3AHPPA derivatives [**(S)-4-amino-3-hydroxy-3-methyl-5-phenylpentanoic** acid] were synthesized as a pair of diastereomers starting from Boc-L-Phe-OH. The absolute configurations of both Me³Sta and Me3AHPPA diastereomers were established by converting the free amino acids to the corresponding trideuteriomethyl ester oxazolidones by reaction with phosgene followed by esterification with ²H₃CI and Cs₂CO₃. ¹³C NMR and ¹H nuclear Overhauser effect difference spectra established the following chiralities for the oxazolidone obtained from Me3AHPPA major diastereomer **(70%) 3S,4S;** minor diastereomer **(30%) 3R,4S.** Similarly the major Me³Sta diastereomer (>90% of mixture) was shown to have the 3S,4S configuration and the minor diastereomer to have the $3R,4S$ configuration. Pepstatin analogues containing the $3R,4S$ diastereomer of Me³Sta or Me³AHPPA are better inhibitors of pepsin and cathepsin D than the corresponding $3S,4S$ diastereomer

Pepstatin, isovaleryl-L-valyl-L-valyl-[(3S,4S)-4-amino-3-hydroxy-6-methylheptanoyl]-L-alanyl-(3S,4S)-4-amino3-hydroxy-6-methylheptanoic acid **(l),** abbreviated Iva-Val-Val-Sta-Ala-Sta, a pentapeptide first isolated by

Umezawa and co-workers^{1b} from bacterial culture broths, is a low-molecular-weight inhibitor of aspartylproteases, e.g., pepsin, renin, and cathepsin **D,2** that *can* lower blood pressure in animal models of hypertension. $3,4$ Numerous pepstatin analogues have been synthesized in **our** laboratory, and their binding to pepsin has been demonstrated kinetically.⁷⁻¹¹ The $(3S)$ -hydroxyl group of statine in the third residue has been shown to be necessary for tightbinding inhibition of pepsin^{5,6} because changing the stereochemistry at C(3) in this essential Sta residue from *S* to R led to a 1000-fold-weaker inhibitor of pepsin. 9 One statine analogue **(4-amino-3-hydroxyl-5-phenylpentanoic** acid, abbreviated AHPPA), derived by replacing the isobutyl side **chain** with a benzyl side **chain, has** been reported and used to prepare the pepstatin analogue, isovaleryl-**Val-(3S,4S)-AHPPA-Ala-Iaa** (Iaa, isoamylamide), an effective inhibitor of pepsin $(K_i = 0.9 \times 10^{-9} \text{ M})$.⁷

We have synthesized analogues of Sta and AHPPA in which the single proton on $C(3)$ is replaced by a methyl group (Me3Sta, Me3AHPPA). During this work it became

(2) Aoyagi, T.; Umezawa, H. *Cold Spring Harbor Conf. Cell Prolif-eration* **1975, 2, 429. (3) Gross, F.;** Lazar, J; **Orth, H.** *Science (Washington, D.C.)* **1972,175,**

656. (4) Miller, R. P.; Poper C. J.; Wilson, C. W.; DeViro, E. *Biochem.*

Pharmacal. **1972,21, 2941. (5) Rich, D. H.; Sun, E. T.; Singh, J.** *Biochem. Biophys. Res. Commun.* **1977,** *74,* **762.**

(6) Rich, D. H.; Sun, E. T. 'Peptides: Proceedings of the Fifth Am-

(9) Rich, D. H.; Sun, E. T. *Biochem. Pharmacal.* **1980,29, 2205. (10) Rich, D. H.; Boparai, A. S.; Bematowicz,** M. *S. Biochem. Biophys.*

Res. Commun. **1982, 104, 1127. (11) Rich, D. H.; Bernatowicz, M.** *S. J. Med. Chem.* **1982,** *25,* **791.**

evident that one diastereomer of both Me3Sta and Me3AHPPA was especially effective as an inhibitor of either pepsin or cathepsin D when incorporated into pepstatin derivatives. An accurate determination of the chirality of this hydroxyl group therefore was needed. We report here a convenient, high-yield synthesis of the 3 methyl Sta and AHPPA derivatives (Me³Sta, Me³AHPPA) suitable for use in peptide synthesis. The determination of the absolute configuration of the $C(3)$ carbon by ¹³C NMR and difference nuclear Overhauser effect techniques is also reported

Results and Discussion

Preparation of the 3-methyl Sta and AHPPA derivatives is shown in Scheme I. The anhydrous Boc-amino acids **2, 3** were allowed to react with methyl lithium in dimethoxyethane (DME). The methyl ketones were isolated in 45-75% yield. Addition of ethyl lithioacetate at -78 $^{\circ}$ C to ketones **4,** and **5** in THF gave 75-78% yields of the esters **6,** and **7,** which were isolated as mixtures of diastereomers. One diastereomer of **6** is formed with a high degree of stereoselectivity (i.e., major isomer: minor isomer $=$ \geq 90:10, based on NMR). On the other hand, the diastereomers of **7** were obtained as a 7030 mixture. Several attempts to separate the respective diastereomers by standard column chromatography over silica gel or by high-pressure liquid chromatography (HPLC) were unsuccessful. However, after coupling the amino acids to L-Ala-Iaa to form the dipeptides 8 and **9,** the diastereomers were successfully separated by standard silica gel chromatography.

Peptides derived from diastereomers of **8a, 8b** and **9a, 9b** were tested as inhibitors of pepsin. We found that peptides containing the minor isomers were consistently better inhibitors of pepsin and cathepsin D than those incorporating the corresponding major diastereomers.12

To assign the stereochemistry at C(3), we prepared the rigid oxazolidone derivative 10 (Scheme I). Me3AHPPA derivative **10** was used because the different intensity of the peaks for the major and minor isomers facilitated their assignment. 13C NMR data established that the peak due to methyl at C(3) in **10** derived from $(3S.4S)$ -Me³AHPPA resonated 4.50 ppm upfield relative to that of the derivative of **10** derived from (3R,4S)- Me3AHPPA (20.58 vs, 25.08 ppm). The same upfield shift was observed for the $C(2)$ carbon (39.61 ppm for $3R,4S$; 44.69 ppm for 3S,4S) in the other diastereomer. These chemical shift differences are due to steric compression¹⁷ between C(5) and an adjacent carbon and are consistent with the assigned stereochemistry. The chemical shifts of carbons at $C(3)$, $C(4)$, and $C(5)$ are identical in both diastereomers.

Difference nuclear Overhauser effect spectra confirm the 13C NMR stereochemical assignment. The deuterated methyl ester 10, prepared by reaction of Cs₂CO₃ and CD₃I with the oxazolidone, was used in order to eliminate overlap of the OCH_3 resonance and the $C(4)$ proton resonance of the minor $3R,4S$ isomer. When the $C(3)$ methyl protons at 1.65 ppm were irradiated, the C(4) proton resonance (3.89 ppm) from the minor isomer was enhanced (8%), establishing that the $C(4)$ H and the $C(3)$ CH₃ groups are close to each other (Figure 1 available in supplementary material). No enhancement of the C(4) proton signal (4.09 ppm) in the major isomer was observed when

⁽¹⁾ (a) Abbreviations used for amino acids follow IUPAC-IUP tentative rules aa described in: *J. Biol. Chem.* **1972,247,977. All amino acids are of the L configuration. Sta, statine or 4-amino-3-hydroxyl-6 methylheptanoic acid; AHPPA, 4-amino-3-hydroxyl-5-phenylpentanoic acid; ha, isovaleryl; Iaa, isoamylamide; Boc, N-tert-butyloxycarbonyl; NMR, nuclear magnetic resonance; DME, dimethoxyethane; THF, tet**rahydrofuran; TLC, thin-layer chromatography; IR, infrared; DIPA, di**isopropylamine; NMM, N-methylmorpholine; HOBT, l-hydroxybenzotriazole; DCC, dicyclohexylcarbodiimide; DMF, dimethylformamide; MqSi, tetramethylsilane. (b) Umezawa, H.; Aoyagi, T.; Morishima, H.; Matausaki, M.; Hamada, H.; Takeuchi, T.** *J. Antibiot.* **1970, 23, 259.**

erican Peptide Symposium, San Diego"; Meienhofer, J., Goodman, M., Eds.; Halsted Press: New York, 1977; p 209.

(7) Rich, D. H.; Sun, E. T.; Ulm, E. J. Med. Chem. 1980, 23, 27.

(8) Rich, D. H.; Sun, E. T. "Peptides 1978"; **Wroclaw, Poland, 1979.**

⁽¹²⁾ Rich, D. H.; Bernatowicz, M. S.; Agarwal, N. S.; Kawai, M.; Salituro, F. G.; Schmidt, P. D.; Hofmann, T., submitted for publication. (13) Rich, D. H.; Sun, E. T.; Boparai, A. S. J. Org. Chem. 1978, 43, **3624.**

the C(3) CH₃ (1.59 ppm) was irradiated. Thus the ¹³C NMR and 'H **NOE** data establish that the absolute configuration of the minor isomer is $3R,4S$ and the configuration of the major isomer is 3S,4S.

The fact that the (3R,4S)-Me³AHPPA and -Me³Sta containing peptides are good inhibitors of pepsin and cathepsin D and better than the 3S,4S derivatives (in some cases by more than 1000-fold) is surprising because in the corresponding Sta or AHPPA peptides the (3S)-hydroxyl derivatives are 1000-fold better inhibitors.⁷⁻¹¹ Thus, assignment of the stereochemistry of these compounds only by comparing their respective kinetic inhibition constants would have given incorrect assignments of chirality. The mechanism of the inhibition of pepsin and cathepsin D by peptides containing these new amino acid derivatives will be reported separately.

Experimental Section

Elemental analyses were performed by Galbraith Labs., Inc., TN. Melting points were determined on a Fischer-Johns melting point apparatus and are uncorrected.

¹³C NMR spectra were recorded on a JEOL FX 90 Q (22.5 KHz) spectrometer. 'H NMR and nuclear Overhauser effect (NOE) data were recorded on a Bruker WH-270 instrument. Procedural details have been reported previously.¹⁴ Chemical shifts are reported as δ units (ppm) relative to Me₄Si (tetramethylsilane) as an internal reference.

Thin-layer chromatography (TLC) was performed on silica gel G plates by using the following solvent systems: (A) 20% ethyl acetate in toluene, (B) 4% methanol in chloroform, (C 6% methanol in chloroform, and (D) 7% methanol in chloroform.

N- (*tert* **-B ut y loxycarbon y 1) -3-amino-5-met hyl-2- hexanone (4).** Anhydrous Boc-leucine (2.9 g, 12.5 mmol, **2)** was dissolved in dimethoxyethane (60 mL) and cooled at 0 $^{\rm o}{\rm C}$ under a nitrogen atmosphere. An ethereal solution of methyl lithium (28 mL of a 1.6 M solution, 37.6 mmol, 3 equiv) then was added dropwise (1 h) to the vigorously (mechanically) stirred solution, and the slightly turbid solution was stirred at *0-5* "C for an additional 5 h. The reaction mixture then was added dropwise to a vigorously stirred ice-water mixture. The ketone was extracted with ether (4 **x** *60* mL). The combined organic phase was washed with brine, dried (MgSO₄), and concentrated in vacuo to afford a pale yellow oil (1.22 g, 43%), which solidified to a waxy solid when stored at -20 \degree for 18 h. TLC analysis showed one major spot: $R_f(A)$ 0.42 (\geq 95%), 0.27 (very minor), 0.14 (very minor). The ketone was used without further purification: IR (neat, thin **film)** 1810 cm⁻¹ (sh) (ketone carbonyl); ¹H NMR (270 MHz, CDCl₃) δ 0.93 1.37-1.76 (m, 12 H, includes singlet at 1.43), 2.20 (3 H, COCH₃), 4.32 (br m, 1 H, α -CH), 4.97 (br, 1 H, NH). $(3 H, J = 6.0 Hz, \text{Leu} \delta\text{-CH}_3), 0.97 (\text{d}, 3 H, J = 6.0 Hz, \text{Leu} \delta\text{-CH}_3),$

N- (*tert* **-Butyloxycarbonyl)-4-amino-3- hydroxy-3,6-dimethylheptanoic Acid Ethyl Ester (Boc-Me3Sta Ethyl Ester, 6).** Following the procedure for the synthesis of Boc-statine ethyl ester,¹³ a hexane solution of *n*-butyllithium (5 mL of a 1.6 M solution, 8 mmol), diisopropyl amine (DIPA) (0.81 g, 8 mmol) in THF (10 mL), ethyl acetate (0.70 g, 8 mmol), and ketone **4** (1.22 g, 5.3 mmol) gave the desired product **6** in 78% yield after purification by silica gel column chromatography (eluting with 6% ethyl acetate in Skellysolve B): mp 61-62 "C.; TLC and HPLC (reversed phase C18 **column,** 63-70% acetonitrile gradient in 0.1% H_3PO_4 in 20 min) gave only a single peak; αl_D -23° (c 1.6, methanol); ¹H NMR (270 MHz, CDCl₃) δ 0.92 (t, 6 H, J = 6 Hz), 1.17 (s, C(3) CH₃ minor isomer), 1.23 (s, C(3) CH₃ major isomer), 1.28 (t, 3 H, *J* = 7 Hz CH, of ethyl) 1.37-1.67 (m, 12 H, includes 1.44, s, Boc), 2.53 (2 H, AB quartet, $J = 14.0$ Hz, $C(2)$ H₂), 3.55 (m, 1 H, C(4) H), 4.00 (s, 1 H, OH), 4.19 (m, 2 H, CH₂ of ethyl), 4.62 (d, 1 H, $J = 9.5$ Hz, NH).

Anal. Calcd for C₁₆H₃₁NO₅: C, 60.54; H, 9.84; N, 4.41. Found: 60.51; H, 9.84; N, 4.40.

N-(tert -Butyloxycarbonyl)-3-amino-4-phenyl-2-butanone (5). The title compound was prepared from Boc-Phe-OH **(3)** (25.00 g, 0.094 mol) and methyl lithium (3 equiv) in DME by the same procedure **as** for preparation of **4;** 18.52 g (74.7%) of **5** was obtained as a semisolid. TLC showed $\geq 95\%$ 5: $R_f(C)$ 0.59 and two very minor spots; 'H NMR (270 MHz, CDC1,) *6* 1.41 **(s,9** H, Boc), 2.13 (s, 3 H, COCH₃), 3.04 (m, 2 H, C(4) H₂), 4.54 (m, 1 H, C(3) H), 5.13 (br d, 1 H, NH), 7.15-7.32 (m, *5* H).

N-(tert **-Butyloxycarbonyl)-4-amino-3- hydroxyl-3 methyl-5-phenylpentanoic Acid Ethyl Ester (Boc-Me3AHPPA Ethyl Ester, 7).** Following the same procedure used to prepare **6,** the title compound was prepared from the ketone **5** (18.36 g, 0.069 mol), DIPA (14.66 mL, 0.10 mol), n-butyllithium (43.75 mL, 2.4 M n-hexane solution], and ethyl acetate (10.2 mL, 0.105 mol). The yield after column chromatography over silica gel (solvent, 15% ethyl acetate in Skellysolve B) was 19.00 g (77.6%): mp 73-74 "C; RAA) 0.21; RAC) *0.64;* 'H *NMR* (270 **MHz,** CDC13) 6 1.15-1.32 (m, 12 H, Boc, CH, of ethyl), 1.36 (s, **3** H, C(3) CH,), 2.43-2.76 (m, 3 H, C(5) H, **C(2)** H), 3.08-3.26 (m, 1 H, C(5) H), 3.76 (m, α -CH of minor isomer), 4.14-4.23 (m, 3 H, CH₂ of ethyl, a-CH of major isomer), 4.32 *(8,* 1 H, OH), 4.47 (d, *J* = 9.6 Hz, NH of minor isomer), 4.66 (d, $J = 9.6$ Hz, NH of major isomer), 7.18-7.30 (m, **5** H, aromatic).

Anal. Calcd for C₁₉H₂₉NO₅; C, 64.93; H, 8.32; N, 3.99. Found C, 65.03; H, 8.49; N, 3.88.

[*N-(tert* **-Butyloxycarbonyl)-4-amino-3- hydroxy-3,6-dimethylheptanoyl]alanine Isoamylamide (8).** Saponification of compound **6** (3.17 g, 0.01 mol) was carried out by using **5** mL of 2 N NaOH in 30 **mL** of dioxane/H20 (2:l) for **5 h;** 2.8 g (96.9%) of pure Boc-Me3&-OH was obtained **as** a syrup. This free acid (2.89 g, 0.01 mol) was coupled with HC1.H-Ala-Iaa derived from Boc-Ala-Iaa' (2.58 g, 0.01 mol) in the presence of NMM (1.1 mL, 0.01 mol), HOBt (1.68 g, 0.011 mol), and DCC (2.06 g, 0.01 mol) in **20** mL of DMF.

The separation of these diastereomers was carried out by silica gel chromatography, eluting with 2% methanol in chloroform: **8a** (pure major isomer, 3S,4S); 3.400 g (79.1%); mp 129-130 "C; $R_f(C)$ 0.37; ¹H NMR (270 MHz, CDCl₃) δ 0.89–0.96 (m, 12 H, Leu δ , δ' -CH₃, 2 H C₃ Iaa), 1.20 (s, 3 H, C(3) CH₃), 1.37-1.68 (m, 18 H, includes 1.45, s, Boc, 1.38, d, $J = 6.5$ Hz, Ala β -CH₃), 2.42 (AB quartet, *J* = 14.0 Hz, **C(2)** H), 3.27 (9, 2 H, *J* = 7.5 Hz, NHCH₂-Iaa), 3.52 (m, 1 H α-CH), 4.45 (quintet, 1 H, $J = 6.5$ Hz, α -CH), 4.57 (s, 1 H, OH), 4.72 (d, 1 H, J = 9.5 Hz, NH), 6.33 (br t, 1 H, Iaa), 6.87 (d, 1 H, *J* = 6.8 Hz NH).

Anal. Calcd for C₂₂H₄₄N₃O₅: C, 61.36; H, 10.30; N, 9.76. Found: C, 61.40; H, 10.07; N 9.68.

8b (pure minor isomer, 344s): 411 mg (9.6%); mp 151-152 $^{\circ}$ C; R_f (C), 0.31. ¹H NMR (270 MHz, CDCl₃) δ 0.87–0.96 (m, 12 H, Leu δ , δ' -CH₃ 2 CH₃ Iaa), 1.12 (s, 3 H, C(3) CH₃), 1.38-1.76 (m, 18 H, includes 1.46, s, Boc), 2.35 (AB quartet, 2 H, *J* = 14.0 Hz, $C(2)$ H), 3.25 (m, 2 H, NHCH₂ Iaa), 3.62 (m, 1 H, α -CH), 4.38-4.48 (m, **2** H, 2 NH), 5.26 (s, 1 H, OH), 6.15 (d, 1 H, *J=* 7.0 Hz, NH), 7.24 (br t, 1 H, NH). An additional 4.3% (183 mg) of a mixture of diastereomers was obtained.

[N-(tert **-Butyloxycarbonyl)-4-amino-3-hydroxyl-3 methyl-5-phenylpentanoyllalanine Isoamylamide (9).** Compound **7** (3.00 g, 8.54 mmol) was saponified (2 N NaOH, 4.27 **mL)** to give 2.65 g (96.3% of the free acid; mp 111-113 "C. The free acid (2.76 **g,** 8.54 mmol) was coupled with HC1-H-Ala-Iaa derived from Boc-Ala-Iaa (2.20 g, 8.5 mmol] using NMM (0.936 ml, 8.5 mmol], HOBt $[1.439 \text{ g}, 9.39 \text{ mmol}]$ and DCC $[1.76 \text{ g}, 8.54 \text{ mmol}]$. The obtained crude product was dissolved in 35 mL of ethyl temperature for 3 h, during which time the pure major isomer (3S,4S) precipitated. The solid was collected, washed with 5 mL of cold ethyl acetate, and dried to give 2.23 g (56.5%). The filtrate was evaporated to dryness. Separation of diastereomers from the residue of the filtrate was carried out by **silica** gel chromatography, eluting with 2% methanol in chloroform. The combined yield of **9a** (pure major isomer, 3S,4S) was 2.51 g (63.4%): $R_f(D)$ 0.49; mp 155-156 °C; ¹H NMR (270 MHz, CDCl₃) δ 0.91 (d, 6 H, *J* = 6.5 Hz, **2** CH, Iaa), 1.13-1.66 (m, 18 H, includes 1.38, d, *J* = 6.0 Hz, Ala β -CH₃, 1.34, s, 3 H, C(3) CH₃, 1.27, s, 9 H, Boc), 2.49 (AB quartet, 2 H, *J* = 14.0 Hz, **C(2)** H), 2.68 (d, 1 H, *J* = 14.0 Hz, C(5) H), 3.27 (q, 2 H, $J = 7.0$ Hz, NHCH₂ Iaa), 3.72 (br m, 1 H, C(4) H), 4.45 (quintet, 1 H, $J = 7.0$ Hz, α -CH), 4.76 (d, 1 H, $J = 9.5$ Hz, NH), 4.93 s, 1 H, OH), 6.28 (br t, 1 H, NH), 6.79 (d, 1 H, *J* = 7.0 Hz, NH), 7.17-7.28 (m, 5 H, aromatic).

⁽¹⁴⁾ Rich, D. H.; Kawai, M.; Jasensky, R. J. *Znt. J. Pept. Protein Res.* **1983,** *21,* **35.**

Anal. Calcd for C₂₅H₄₂N₃O₅: C, 64.63; H, 9.11; N, 9.04. Found: C, **64.75;** H, **8.91;** N **9.04.**

9b (pure minor isomer, **3R,4S): 540** mg **(13.6%);** mp **156-157** 6.0 Hz, **2** CH3 Iaa), **1.23-1.74** (m, **18** H, includes **1.23,s) C(3)** CH3, **1.28, s, Boc, 1.40, d,** $J = 6.5$ **Hz, Ala** β **-CH₃), 2.31-2.55 (m, 3 H,** C(5) H, C(2) H), **3.17** (m, **2** H, NHCHz Iaa), **3.42** (br dd, **1** H, C(5) H), **3.78** (m, **1** H, **C(4)** H), **4.37-4.48** (m, **2** H, a-CH, NH), **5.58** *(8,* **1** H, OH), **6.16** (d, **1** H, J ⁼**6.5** Hz, NH), **7.15-7.28** (m, **6** H, NH, aromatic). An additional **665** mg **(16.8%)** mixture of diastereomers was obtained. \degree C, $R_A(D)$ 0.44; ¹H NMR (270 MHz, CDCl₃) δ 0.86 (d, 6 H, J =

[2H3]Methyl **(4S)-Benzyl-5-methyloxazolidone-5-acetate (10).** The oxazolidone ring system was prepared by the method reported for the synthesis of a homologue.^{7} Starting with compound **7 (1.408** g, **4** mmol), **536** mg **(54.0%) 295%** pure *oxazo*lidone carboxylic acid was obtained as a semisolid.

Esterification of this acid **(536** mg, **2.17** mmol) was carried out by reaction with Cs2C03 **(1.70** mL of **20%** aqueous solution) and $CD₃I$ (0.149 mL, 2.39 mmol) as reported.¹⁵ The ester was then

(15) Wang, S. S.; Gisin, B. F.; Winter, D. P.; Makofske, R.; Kulesha, I. D.; Tzougraki, C.; Meinenhofer, J. *J. Org. Chem.* **1977, 42, 1286.**

purified by silica gel chromatography, eluting with **1%** methanol in chloroform to give **463** mg (80.8%) of pure **10.**

Acknowledgment. This work was supported by a grant from the National Institutes of Health (No. AM 20100).

Registry **No. 2, 13139-15-6; 3, 13139-15-6; 4, 85613-63-4; 5,** 85613-61-2; (3S,4S)-7 free acid, 85613-67-8; (3S,4S)-8a, 85613-68-9; **(3R,4S)-8b, 85613-69-0; (3S,4S)-9a, 85613-70-3; (3R,4S)-9b, 85613-71-4; 10, 85613-72-5;** Boc-Ala-Iaa, **72155-58-9;** H-Ala-**Iaa.HC1,72155-60-3;** Boc-Me3Sta-OH, **85613-73-6;** ethyl acetate, 85613-64-5; (3S,4S)-6, 85613-65-6; (3S,4S)-7, 85613-66-7; (3R,4S)-7, **141-78-6.**

Supplementary Material Available: Full NMR NOE data and spectra for compound **10 (1** page). Ordering information is given on any current masthead page.

(16) Nakanishi, K.; Schooley, D. A.; Koreeda, M.; Muira, I. *J. Am.* **(17) Jager, Y.; Buss, V.** *Liebigs Ann. Chem.* **1980, 101.** *Chem. SOC.* **1972,94,2865.**

General-Base Catalysis in the Reaction of Water with Activated Aromatic Substrates. The Hydrolysis of 3-Methyl-1-picrylimidazolium Ion

Rita H. de Rossi* and Alicia Veglia

Departamento de Quimica Orgiinica, Facultad de Ciencias Quimicas, Universidad Nacional de CBrdoba, Sucursal **16,** *CC* **61, 5016** *Cbrdoba, Argentina*

Received November 17, 1982

The rate of hydrolysis of **3-methyl-1-picrylimidazolium** ion was investigated between pH **1.7** and **9.3** in the presence of several buffer bases at various concentrations. The reaction is strongly catalyzed by oxygen bases. The catalytic constants including water and OH- are spread over a range of ten powers of ten **and** show a good Brønsted correlation with $\beta = 0.62$. The kinetic solvent isotopic effect for the water-, acetate-, and OH⁻-catalyzed reactions are **2, 0.86,** and **0.84,** respectively. The mechanism of catalysis is discussed, and it is concluded that it represents concerted addition of water to the aromatic ring.

The reaction of water and alcohols with the carbonyl carbon occurs by a concerted mechanism with an important component of proton transfer in a mobile transition state.¹

This mechanism is supported by a large number of structure-reactivity correlations which provide evidence for a fully concerted mechanism.2

Similar results have been found for the addition-elimination of alcohols to activated aromatic compounds (eq 1)³ where the general base-acid catalysis was interpreted in terms of a concerted mechanism.

⁽¹⁾ Palmer, J. L.; Jencks, W. P. J. *Am. Chem. SOC.* **1980,102,6472 and references cited therein. 5883.**

On the other hand, the reaction of water with activated aromatic substrates is known in less detail mainly because most aromatic nucleophilic substitution reactions have been studied at high pH where the hydroxide ion catalyzed reaction is predominant. It has been suggested that water addition to 4,6-dinitrobenzofuroxan occurs through a concerted mechanism.⁴ Also related are the studies on pseudobase formation from water addition to quaternary nitrogen heterocycles.6

We recently reported a study of the hydrolysis of Npicrylimidazole **(1)** and interpreted the general buffer catalysis observed along the same lines.6 At low pH, the reaction folows the rate law of eq 2, where the term k_{SH}

$$
v = k_0[S] + k_s[S][B] + k_{SH}[S][BH] \tag{2}
$$

was attributed to the reaction of water with N -picrylimidazolium cation **(2),** catalyzed by general bases, but this mechanism is kineticaly indistinguishable from others that involve **1** and a general-acid catalyst in the transition state. **EXERIMAGE AND THE INCREDITED ASSES AND THE PROPERTY AND THE PROPERTY AND TRIST OF A ROH THE PROPERTY AND PROPERTY AN** picrylimidazolium cation **(3)** which is expected to be a **good** model for **2.**

⁽²⁾ Jencks, W. P. *Acc. Chem. Res.* **1980,13, 161. (3)** boasconi, **C. F.; Gander, J. R. J. Am.** *Chem. SOC.* **1978,100,8117.**

⁽⁴⁾ Terrier, F.; Millot, F.; Norris, W. P. *J. Am. Chem. SOC.* **1976, 98,**

⁽⁵⁾ Bunting, J. W.; Meathrel, W. G. *Can. J. Chem.* 1973, 51, 1965.
(6) de Rossi, R. H.; de Vargas, E. B. *J. Am. Chem. Soc.* 1981, 103, 1533.